Hepatotrophic effects of FK506 in dogs.

PubWeight™: 2.39‹?› | Rank: Top 2%

🔗 View Article (PMC 2967279)

Published in Transplantation on January 01, 1991

Authors

T E Starzl1, K A Porter, V Mazzaferro, S Todo, J Fung, A Francavilla

Author Affiliations

1: Department of Surgery, University of Pittsburgh, PA 15213.

Articles citing this

Kidney transplantation under FK 506. JAMA (1990) 7.45

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: expression of biologically active recombinant ALR and demonstration of tissue distribution. Proc Natl Acad Sci U S A (1994) 2.35

Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31

Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59

A fresh look at augmenter of liver regeneration in rats. Hepatology (1999) 1.32

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol (1992) 1.32

Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. Hepatology (1991) 1.30

Cell proliferation and oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on bile duct cells. Hepatology (1995) 1.27

Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18

Analysis of the structure and expression of the augmenter of liver regeneration (ALR) gene. Mol Med (1996) 1.16

Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. Hepatology (1991) 1.13

Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology (1992) 1.06

The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions. Hepatology (1997) 1.04

FK 506 versus cyclosporine. Transplant Proc (1993) 1.03

Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. Transplantation (1991) 1.01

Hepatic regeneration and growth factors. J Surg Oncol Suppl (1993) 1.01

Inhibition of liver, kidney, and intestine regeneration by rapamycin. Transplantation (1992) 1.00

Effect on the canine Eck fistula liver of intraportal TGF-beta alone or with hepatic growth factors. Hepatology (1992) 0.89

Liver transplantation for type I and type IV glycogen storage disease. Eur J Pediatr (1993) 0.89

Donor age affects liver regeneration during early period in the graft liver and late period in the remnant liver after living donor liver transplantation. World J Surg (2012) 0.89

The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. Transplant Proc (1991) 0.84

Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc (1991) 0.83

Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro. World J Gastroenterol (2005) 0.83

Effects on in vivo and in vitro hepatocyte proliferation of methylprednisolone, azathioprine, mycophenolic acid, mizoribine, and prostaglandin E1. Transplant Proc (1992) 0.78

Effect of cyclosporine on hepatic energy status and on fructose metabolism after portacaval shunt in dog as monitored by phosphorus-31 nuclear magnetic resonance spectroscopy in vivo. Hepatology (1991) 0.77

Metabolic scaling predicts posthepatectomy liver regeneration after accounting for hepatocyte hypertrophy. Liver Transpl (2016) 0.75

Hepatic growth effects of methylprednisolone, azathioprine, mycophenolic acid, and mizoribine. Transplantation (1993) 0.75

Articles cited by this

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature (1989) 8.48

Kidney transplantation under FK 506. JAMA (1990) 7.45

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature (1989) 7.02

Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature (1989) 5.86

Cyclosporine. N Engl J Med (1989) 5.67

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 5.53

A quantitative stereological description of the ultrastructure of normal rat liver parenchymal cells. J Cell Biol (1968) 4.95

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Growth-stimulating factor in regenerating canine liver. Lancet (1979) 2.61

The ninaA gene required for visual transduction in Drosophila encodes a homologue of cyclosporin A-binding protein. Nature (1989) 2.54

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

The hepatotropic influence of cyclosporine. Surgery (1990) 2.27

Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01

The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim Biophys Acta (1985) 1.75

Cyclosporine A augments the regenerative response after partial hepatectomy in the rat. Transplant Proc (1988) 1.64

Cyclosporin A stimulates proliferation of the liver cells after partial hepatectomy in rats. Surg Gynecol Obstet (1988) 1.60

EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59

FK 506 as a growth control factor. Transplant Proc (1990) 1.36

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Baboon-to-human liver transplantation. Lancet (1993) 4.01

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Cadaveric renal transplantation. An analysis of 65 cases. Lancet (1969) 3.48

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92

Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87

Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82

Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81

Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64

Growth-stimulating factor in regenerating canine liver. Lancet (1979) 2.61

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

Studies of blood flow and ultrastructural changes in rejecting and nonrejecting canine orthotopic liver homografts. Surgery (1968) 2.58

Detection of circulating immune complexes in pathological human sera. Lancet (1975) 2.51

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Liver transplantation, 1980, with particular reference to cyclosporin-A. Transplant Proc (1981) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus. Ann Surg (1978) 2.48

Portal diversion for the treatment of glycogen storage disease in humans. Ann Surg (1973) 2.44

Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

The Eck fistula in animals and humans. Curr Probl Surg (1983) 2.35

Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: expression of biologically active recombinant ALR and demonstration of tissue distribution. Proc Natl Acad Sci U S A (1994) 2.35

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

Portacaval shunt in patients with familial hypercholesterolemia. Ann Surg (1983) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28

The hepatotropic influence of cyclosporine. Surgery (1990) 2.27

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

SEROTYPING FOR HOMOTRANSPLANTATION. VII. SELECTION OF KIDNEY DONORS FOR THIRTY-TWO RECIPIENTS. Ann N Y Acad Sci (1966) 2.25